The pharmaceutical company, Pfizer, has decided to not break up into two publicly-traded companies, ending Wall Street speculation regarding the company’s future for now. Pfizer announced Monday (today) that they believed they can maximize their shareholder value as the company is now, but “it reserves the right to split in the future if the situation changes.” Their original discussion to split came from the idea that two companies would grow faster than one. However, the likelihood of such a decision began to fade this summer when Pfizer enjoyed rising sales from newly-developed drugs and rising prospects for their drugs still under development. “The drugmaker’s most likely path forward involves hunting for more acquisition targets, according to Bernstein analyst Dr. Tim Anderson.”
You can read the Star Telegram’s article about Pfizer’s decision here.